{"product_id":"international-myeloma-society-7th-immune-effector-cell-therapies-in-multiple-myeloma-workshop-2026","title":"International Myeloma Society 7th Immune Effector Cell Therapies in Multiple Myeloma Workshop 2026","description":"\u003cul\u003e\n  \u003cli\u003eInclude:  videos + file sub vtt +  pdf, size:  GB\u003c\/li\u003e\n  \u003cli\u003eTarget Audience: hematologists, medical oncologists, immunologists\u003c\/li\u003e\n  \u003cli\u003eSample video: contact me for sample video\u003c\/li\u003e\n  \u003cli\u003eInformation:\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eLearning Objectives\u003c\/p\u003e\n\u003ch3\u003eUpon completion of this workshop, participants will be able to:\u003c\/h3\u003e\n\u003cp\u003eEvaluate the latest clinical updates and real-world data for various CAR T cell therapies (Ide-cel, Cilta-cel, Anito-cel, GC012F) and bispecific antibodies (Teclistamab, Talquetamab, Elranatamab, Linvoseltamab).\u003c\/p\u003e\n\u003cp\u003eAnalyze novel therapeutic approaches, including trispecific antibodies, combination therapies, and dual-targeted CAR T cells.\u003c\/p\u003e\n\u003cp\u003eIdentify and manage toxicities associated with T cell engaging therapies, such as CAR-T-associated delayed neurotoxicity and immune effector cell enterocolitis.\u003c\/p\u003e\n\u003cp\u003eUnderstand the genomic drivers and microenvironmental factors contributing to response and resistance in BCMA and GPRC5D-targeted therapies.\u003c\/p\u003e\n\u003cp\u003eApply practical strategies for optimizing the administration and sequencing of immune therapies in clinical settings.\u003c\/p\u003e\n\u003cp\u003eTarget Audience\u003c\/p\u003e\n\u003cp\u003eThe IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.\u003c\/p\u003e\n\u003cp\u003eBest for hematologists, medical oncologists, immunologists, clinical researchers, and scientists.\u003c\/p\u003e\n\u003cp\u003eTopics\u003c\/p\u003e\n\u003cp\u003eSESSION 1: CLINICAL UPDATES ON CART CELLS\u003c\/p\u003e\n\u003cp\u003eIde-cel and Cilta-cel: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eLatest Real World Data for CAR T Cells\u003c\/p\u003e\n\u003cp\u003eUpdate on Anito-cel and GC012F\u003c\/p\u003e\n\u003cp\u003eGPRC5D CAR T Cells: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eDual-targeted CAR T Cell Approaches\u003c\/p\u003e\n\u003cp\u003eUpdate on Allogeneic CAR T Cell Approaches\u003c\/p\u003e\n\u003cp\u003eSESSION 2: CLINICAL UPDATES ON BISPECIFIC ANTIBODIES\u003c\/p\u003e\n\u003cp\u003eTeclistamab and Talquetamab for Relapsed MM: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eElranatamab and Linvoseltamab for Relapsed MM: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eReal World Data for Bispecific Antibodies\u003c\/p\u003e\n\u003cp\u003eEtentamig and Cevostamab: Latest Updates and Ongoing Trials\u003c\/p\u003e\n\u003cp\u003eSESSION 3: NOVEL APPROACHES IN THE CLINIC\u003c\/p\u003e\n\u003cp\u003eTrispecific Antibodies for Myeloma\u003c\/p\u003e\n\u003cp\u003eCombining Bispecific Abs with CAR T Cells\u003c\/p\u003e\n\u003cp\u003eFixed Duration Bispecific Antibody Therapy\u003c\/p\u003e\n\u003cp\u003eAugmenting T Cell Therapies with Proteasome Inhibitors\u003c\/p\u003e\n\u003cp\u003eTriPRIL CAR T Cells\u003c\/p\u003e\n\u003cp\u003eBispecific with Anti-CD38 Antibody\u003c\/p\u003e\n\u003cp\u003eSESSION 4: TOXICITIES OF T CELL ENGAGING THERAPIES\u003c\/p\u003e\n\u003cp\u003ePre-treatment Parameters Predicting CAR T Cell Toxicities\u003c\/p\u003e\n\u003cp\u003eElevated ALC and CAR T Cell Toxicities\u003c\/p\u003e\n\u003cp\u003eManaging CAR-T-associated Delayed Neurotoxicity\u003c\/p\u003e\n\u003cp\u003eCAR T-related Lymphomas: Clinical and Mechanistic Insights\u003c\/p\u003e\n\u003cp\u003eSESSION 5: PRACTICAL CONSIDERATIONS FOR IMMUNE THERAPIES\u003c\/p\u003e\n\u003cp\u003eSequencing BCMA-directed Therapies: How to Choose?\u003c\/p\u003e\n\u003cp\u003eOptimizing Outpatient Bispecific Ab and CAR T Cell Administration\u003c\/p\u003e\n\u003cp\u003eManaging Extramedullary Disease with T cell-redirecting Therapies\u003c\/p\u003e\n\u003cp\u003eT Cell Therapies for CNS Myeloma\u003c\/p\u003e\n\u003cp\u003eImpact of CHIP on Outcomes after CAR T Cell Therapy\u003c\/p\u003e\n\u003cp\u003eSESSION 6: UNDERSTANDING RESPONSE AND RESISTANCE TO T CELL THERAPIES\u003c\/p\u003e\n\u003cp\u003eGenomic Drivers of Resistance to BCMA-targeted Therapies\u003c\/p\u003e\n\u003cp\u003eMechanisms of Antigen Escape following GPRC5D-targeted Therapies\u003c\/p\u003e\n\u003cp\u003eImmune Correlates of Response to BCMA CAR T Cells\u003c\/p\u003e\n\u003cp\u003eMicroenvironmental Factors Impacting Response\/resistance\u003c\/p\u003e\n\u003cp\u003eImmune Correlates of Resistance to Bispecific Antibodies\u003c\/p\u003e\n\u003cp\u003eSESSION 7: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 1\u003c\/p\u003e\n\u003cp\u003eEvaluating Immune Fitness Across the Stages of MM Progression\u003c\/p\u003e\n\u003cp\u003eTargeting S100A8\/9 to Enhance T Cell Therapies\u003c\/p\u003e\n\u003cp\u003eOvercoming T Cell Exhaustion\u003c\/p\u003e\n\u003cp\u003eModulating the Microbiome to Enhance CAR T Cell Therapy\u003c\/p\u003e\n\u003cp\u003eSESSION 8: STRATEGIES TO IMPROVE IMMUNE EFFECTOR CELL THERAPY, PART 2\u003c\/p\u003e\n\u003cp\u003eNovel T Cell Therapy Targets for Myeloma\u003c\/p\u003e\n\u003cp\u003eCAR T Cells Against CD70\u003c\/p\u003e\n\u003cp\u003eTargeting Intra-cellular Targets\u003c\/p\u003e\n\u003cp\u003eEZH1\/2 inhibition to augment cellular therapy\u003c\/p\u003e\n\u003cp\u003eSESSION 9: CHALLENGING CASES IN IMMUNE EFFECTOR CELL THERAPY\u003c\/p\u003e\n\u003cp\u003eCAR T Cell Therapy in a Patient with Plasma Cell Leukemia\u003c\/p\u003e\n\u003cp\u003eImmune Effector Cell Enterocolitis: A Novel Clonal Lymphoproliferative Disorder?\u003c\/p\u003e\n\u003cp\u003eFatal HLH Following GPRC5D×CD3 Therapy: Lessons from Genetic and Infectious Co-factors\u003c\/p\u003e\n\u003cp\u003eSESSION 10: IN VIVO APPROACHES\u003c\/p\u003e\n\u003cp\u003eScience of In Vivo CAR T Cell Therpay\u003c\/p\u003e\n\u003cp\u003eBedside CAR T Cell Production\u003c\/p\u003e\n\u003cp\u003eIn Vivo Bispecific Therapy\u003c\/p\u003e\n\u003cp\u003eClinical Results of In Vivo CAR T Cell Therapy\u003c\/p\u003e\n\u003cp\u003eClinical Results of In Vivo CAR T Cell Therapy Part II\u003c\/p\u003e","brand":"Medicalcoursespro","offers":[{"title":"Default Title","offer_id":46405757993156,"sku":null,"price":52.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0751\/7644\/4100\/files\/International-Myeloma-Society-7th-Immune-Effector-Cell-Therapies-in-Multiple-Myeloma-Workshop-2026.jpg?v=1784215803","url":"https:\/\/medicalcoursespro.com\/products\/international-myeloma-society-7th-immune-effector-cell-therapies-in-multiple-myeloma-workshop-2026","provider":"Medicalcoursespro","version":"1.0","type":"link"}